International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1243-1252 , 1 August 2001

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

  • Miljenko V. Pilepich, M.D.

      Affiliations

    • Department of Radiation Oncology, Ann Arbor Regional CCOP, Ann Arbor, MI, USA
    • Corresponding Author InformationReprint requests to: Miljenko V. Pilepich, Department of Radiation Oncology, P.O. Box 995, Ann Arbor, MI 48106. Tel: (734) 712-3595; Fax: (734) 712-5344
    • ,
  • Kathryn Winter, M.S.

      Affiliations

    • Radiation Therapy Oncology Group, Philadelphia, PA, USA
    • ,
  • Madhu J. John, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California, San Francisco, CA, USA
    • ,
  • John B. Mesic, M.D.

      Affiliations

    • Radiation Oncology Center, Sacramento, CA, USA
    • ,
  • William Sause, M.D.

      Affiliations

    • Department of Radiation Oncology, LDS Hospital, Salt Lake City, UT, USA
    • ,
  • Phillip Rubin, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Rochester, Rochester, NY, USA
    • ,
  • Colleen Lawton, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
    • ,
  • Mitchell Machtay, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
    • ,
  • David Grignon, M.D.

      Affiliations

    • Department of Pathology, Wayne State University, Detroit, MI, USA

Received 3 January 2001 ,Revised 28 February 2001 ,Accepted 20 March 2001.

References 

  1. Pilepich MV, Krall JM, Al-Sarraf M, et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma (A randomized comparative trial of the Radiation Therapy Oncology Group). Urology. 1995;45:616–623
  2. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;52:457–481
  3. Gray RL. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  4. Pilepich MV, Krall JM, Sause WT, et al.  Prognostic factors in carcinoma of the prostate—Analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys. 1987;13:339–349
  5. Aus G, Abrahamsson P-A, Ahlgren F, et al.  Hormonal treatment before radical prostatectomy (A 3-year follow-up). J Urol. 1998;159:2013–2017
  6. Goldenberg SL, Klotz LH, Srigley J, et al.  Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in treatment of localized prostate cancer. J Urol. 1996;156:873–877
  7. Soloway MS, Sharifi R, Wajsman Z, et al.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 1995;154:424–428
  8. Witjes WPJ, Schulman CC, Debruyne FMMJ. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-2N0M0 prostatic carcinoma. Urology. 1997;49:65–69
  9. Dalkin BL, Ahmann FR, Nagle R, et al.  Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. 1996;155:1357–1360
  10. Bonney WW, Schned AR, Timberlake DS. Neoadjuvant androgen ablation for localized prostatic cancer. Pathology methods, surgical end points and meta-analysis of randomized trials. J Urol. 1998;160:1754–1760
  11. Zelefsky MJ, Leibel SA, Burman CM, et al.  Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1994;29:755–761
  12. Green N, Bodner H, Broth E, et al.  Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys. 1984;10:971–976
  13. Laverdiere J, Gomez JL, Cusan L, et al.  Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995;37:247–252
  14. Zietman AL, Prince EA, Nakfoor BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate (Experimental and clinical results). Urology. 1997;49:74–83
  15. Zietman AL, Nakfoor BN, Prince EA, Gerweck LE. The effect of androgen deprivation on an androgen sensitive tumor; an in vivo and in vitro study. Cancer J Sci Am. 1997;3:31–36
  16. Pilepich MV, Caplan R, Byhardt R, et al.  Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy—report of RTOG protocol. J Clin Oncol. 1997;15:1013–1021

☆ Supported by Public Health Service grants CA-21661 and CA-32115 from the National Cancer Institute, National Institute of Health, Department of Health and Human Services.

PII: S0360-3016(01)01579-6

International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1243-1252 , 1 August 2001

Article Tools

* Image Usage & Resolution